Two Families Revolutionize Rare Disease Advocacy in Massachusetts

News Summary

The Dion and Bailey families are reshaping patient advocacy for rare diseases, specifically Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C), at the Massachusetts Biotechnology Council’s 2025 Patient Advocacy Summit. Their partnership has created a revolutionary model that brings together families, researchers, and industry partners to accelerate innovation and enhance support for affected individuals. The summit showcased their impactful stories and the ongoing commitment of the Massachusetts biotech community to patient-centered initiatives.

Cambridge, Massachusetts – Two families are fundamentally reshaping the landscape of patient advocacy for rare diseases, demonstrating the profound impact of persistence and collaboration within the Massachusetts biotechnology community. The Dion and Bailey families, whose children are affected by Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C), were prominently featured at the Massachusetts Biotechnology Council’s (MassBio) 2025 Patient Advocacy Summit, held on December 11, 2025, in Cambridge, Massachusetts. Their journey highlights a new model for how rare disease communities and industry partners can work together to accelerate innovation and deliver tangible results for patients.

A Unified Front Against Rare Disease

The core of this advocacy revolution lies with the Dion and Bailey families. Courtney and Joe Dion’s path began in the summer of 2022 when their eldest son, Peter, showed difficulties with routine movements. Tests confirmed the diagnosis of LGMD2C, a severe childhood-onset subtype of muscular dystrophy. Soon after, their youngest daughter, Maggie, also received the diagnosis. Chrissy and Brian Bailey’s daughters, six-year-old Berkley and eight-year-old Kennedy, endured nearly a year of misdiagnoses and dismissals before bloodwork revealed significantly elevated Creatine Kinase (CK) levels. These parallel journeys of heartbreak and determination have forged a powerful partnership.

Together, the Dions and Baileys lead the Dion Foundation, an advocacy organization that has pioneered an innovative model for collaborative action. This structure allows families to unite under a shared umbrella, featuring both a general fund and individual family funds, thereby acknowledging the unique nature of each LGMD journey while fostering collective purpose. This collaborative spirit, coupled with relentless hope, is crafting a new blueprint for rare disease advocacy, one that effectively brings together families, researchers, and the biotechnology industry around a common mission: ensuring that no child is defined by their diagnosis.

Celebrating Progress at the MassBio Summit

The 2025 MassBio Patient Advocacy Summit provided a platform to amplify these compelling narratives. Nine-year-old Maggie Dion delivered a powerful address, articulating her vision for a future where no child suffers from a curable disease and emphasizing that “Love can change science, and families can change the world”. Her presence underscored the human element at the heart of rare disease advocacy, leaving attendees both silent and energized.

The summit, themed “Purpose, In Spite of Pressure,” highlighted the commitment to driving breakthroughs even amidst the immense challenges inherent in biotech and healthcare. For industry professionals, this means keeping patients central as market forces evolve. For advocates and researchers, it translates personal challenges into systemic change. For patients and families, it means drawing strength from shared stories and collective action. The direct impact of patient advocacy was evident in Maggie’s recent experience. After six months on a clinical trial, her legs no longer hurt, and Peter, who once experienced easy fatigue, is now able to play outside for extended periods. These personal successes exemplify how patient leadership directly fuels progress.

MassBio’s Advocacy for Systemic Change

The Massachusetts Biotechnology Council, located in Cambridge, Massachusetts, actively supports patient advocacy by elevating patient stories through events like the Patient Advocacy Summit and Rare Disease Day. MassBio’s policy initiatives also play a critical role, focusing on securing national priorities such as the preservation of orphan drug incentives and the restoration of full Research and Development (R&D) expensing. These measures are designed to encourage crucial follow-on investment into rare disease research and allow emerging companies to immediately deduct R&D costs, thereby fostering innovation and accessibility for patients.

Wider Efforts in the Rare Disease Community

Understanding Rare Diseases

The challenges faced by families like the Dions and Baileys are widespread within the rare disease community. On average, individuals living with rare diseases experience a waiting period of five years between their first symptoms and receiving an accurate diagnosis. More than half of these patients wait at least six months after their initial medical consultation before getting answers. Globally, approximately one in every ten people lives with a rare disease diagnosis, underscoring the broad impact of these conditions. Rare diseases affect nearly 30 million Americans and countless others worldwide, emphasizing the critical need for continued advocacy and research.

State-Level Advocacy and Support

Across the United States, various organizations are driving significant advocacy efforts. In Michigan, the MI-RARE (Michigan Rare Coalition) is dedicated to improving the quality of life for all Michigan residents affected by rare conditions. They hosted the Michigan Rare Disease State Advocacy Day at the Capitol on September 30, 2025, offering a crucial opportunity for patients, families, and caregivers to engage with state legislators and advocate for important rare disease issues. This initiative, a partnership with the EveryLife Foundation for Rare Diseases, focuses on awareness, advocacy, and education at the state level.

The Bonnell Foundation is another prominent advocate, specifically for patients with Cystic Fibrosis (CF). Founded by Laura Bonnell, whose two adult daughters live with CF, the foundation works to raise awareness about the disease and address concerns regarding prescription drug affordability boards, which could potentially harm research and development. This foundation provides support for the day-to-day expenses associated with living with CF.

National and Global Initiatives

On a national level, the Patient Advocate Foundation (PAF) provides essential services to Americans with chronic, life-threatening, and debilitating illnesses nationwide. Established in 1996, PAF offers professional case management services, including free and confidential navigational assistance with financial and practical challenges that impact healthcare access. PAF received the 2024 RDDC Patient Advocacy RISE Award, recognizing its steadfast commitment and outstanding efforts in addressing the unique challenges faced by those affected by rare diseases.

For individuals with extremely rare conditions, the n-Lorem Foundation, a non-profit organization based in California, focuses on developing and providing personalized experimental Antisense Oligonucleotide (ASO) medicines for nano-rare patients. Nano-rare refers to genetic mutations found in only 1 to 30 patients globally. n-Lorem commits to providing these individualized treatments for free, for life. As of late 2024, n-Lorem had treated 15 patients and projected to treat over 25 by the end of that year, demonstrating significant progress in this specialized field. The foundation also held its second annual Nano-rare Patient Colloquium in Cambridge, Massachusetts, on October 30-31, 2024, bringing together patients, physicians, and partners.

In the biopharmaceutical industry, companies like Gilead Sciences contribute to addressing unmet medical needs. Headquartered in Foster City, California, Gilead focuses on researching and developing antiviral drugs for conditions such as HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. Their research scholars program supports new investigations into rare liver disease, reflecting a broader commitment to scientific innovation in areas of high unmet need.

Frequently Asked Questions (FAQ)

What rare disease do the Dion and Bailey families advocate for?

The Dion and Bailey families advocate for patients affected by Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C), a severe childhood-onset subtype of muscular dystrophy.

What is the significance of the 2025 MassBio Patient Advocacy Summit?

The 2025 MassBio Patient Advocacy Summit, held on December 11, 2025, in Cambridge, Massachusetts, highlighted the stories of families like the Dions and Baileys, showcasing how persistence and collaboration are redefining rare disease advocacy and driving innovation.

What is the average waiting period for a rare disease diagnosis?

On average, people living with rare diseases wait five years between their first symptoms and receiving an accurate diagnosis.

What is the mission of the n-Lorem Foundation?

The n-Lorem Foundation, a non-profit based in California, discovers, develops, and provides personalized experimental Antisense Oligonucleotide (ASO) medicines for nano-rare patients for free, for life. Nano-rare refers to genetic mutations found in only 1 to 30 patients worldwide.

What services does the Patient Advocate Foundation (PAF) provide?

The Patient Advocate Foundation (PAF) is a national non-profit that provides professional case management services and financial aid to Americans with chronic, life-threatening, and debilitating illnesses, offering free and confidential navigational assistance with financial and practical healthcare access challenges nationwide.

What is the Michigan Rare Disease State Advocacy Day?

The Michigan Rare Disease State Advocacy Day, hosted by the MI-RARE (Michigan Rare Coalition) on September 30, 2025, is an opportunity for patients, families, and caregivers to advocate for rare disease issues with state legislators in Michigan. This initiative is state-level.

Key Features of Rare Disease Patient Advocacy

Deeper Dive: News & Info About This Topic

Tom Fowler Law Enhances Case Management in Des Moines
Positive Outlook Fuels Cancer Advocacy
Patient-Investigator Collaboration at SABCS 2025
Mark Lawler Stresses Importance of Patient Advocacy in Cancer Research
Families Lead the Charge in Redefining Rare Disease Patient Advocacy